US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5824683A
(en)
*
|
1995-11-28 |
1998-10-20 |
Schering Corporation |
2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
|
ZA969888B
(en)
*
|
1995-11-28 |
1997-05-26 |
Schering Corp |
2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6133271A
(en)
*
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
US6403799B1
(en)
*
|
1999-10-21 |
2002-06-11 |
Agouron Pharmaceuticals, Inc. |
Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
ATE395349T1
(de)
*
|
2001-08-28 |
2008-05-15 |
Schering Corp |
Polycyclische guanin phosphodiesterase inhibitoren
|
EP1790652A1
(fr)
*
|
2001-08-28 |
2007-05-30 |
Schering Corporation |
Guanines polycycliques comme inhibiteurs de la phosphodiésterase V
|
WO2003020702A2
(fr)
*
|
2001-08-31 |
2003-03-13 |
The Rockefeller University |
Activite de phosphodiesterase et regulation de la signalisation a mediation par phosphodiesterase 1-b dans le cerveau
|
US6943171B2
(en)
*
|
2001-11-09 |
2005-09-13 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase V inhibitors
|
EP1719772A1
(fr)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Procédé de préparation d'inhibiteurs de la phosphodiesterase v de la xanthine et leur précurseurs
|
CN1860119A
(zh)
*
|
2003-07-31 |
2006-11-08 |
先灵公司 |
用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
|
KR20060101762A
(ko)
*
|
2003-11-21 |
2006-09-26 |
쉐링 코포레이션 |
포스포디에스테라제 v 억제제 제형
|
SE0401653D0
(sv)
*
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
New compounds
|
WO2006104870A2
(fr)
*
|
2005-03-25 |
2006-10-05 |
Schering Corporation |
Methodes de traitement d'hyperplasie prostatique benigne ou de symptomes des voies urinaires inferieures faisant appel a des inhibiteurs de pde 5
|
WO2006133261A2
(fr)
*
|
2005-06-06 |
2006-12-14 |
Intra-Cellular Therapies, Inc. |
Composes organiques
|
EP1919287A4
(fr)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
Composés organiques pour traiter un signald'activité réduit du récepteur de la dopamine
|
WO2007073300A1
(fr)
|
2005-12-23 |
2007-06-28 |
Astrazeneca Ab |
Modulateurs des récepteurs gaba-b
|
US7745474B2
(en)
|
2005-12-23 |
2010-06-29 |
Astrazeneca Ab |
Imidazole derivatives for the treatment of gastrointestinal disorders
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
JP5453086B2
(ja)
*
|
2006-06-06 |
2014-03-26 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
ES2411604T3
(es)
|
2006-11-13 |
2013-07-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
US9006258B2
(en)
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
US7901872B2
(en)
|
2007-05-21 |
2011-03-08 |
Macronix International Co., Ltd. |
Exposure process and photomask set used therein
|
RU2010101611A
(ru)
*
|
2007-06-21 |
2011-07-27 |
Шеринг Корпорейшн (US) |
Полициклические производные гуанина и способы их применения
|
DK2240490T3
(da)
|
2007-12-06 |
2013-12-16 |
Takeda Pharmaceutical |
Organiske forbindelser
|
EP2240028B1
(fr)
*
|
2007-12-06 |
2016-07-20 |
Intra-Cellular Therapies, Inc. |
Dérivés de Pyrazolopyrimidine-4,6-dione et leur utilisation pharmaceutique
|
WO2009144548A1
(fr)
*
|
2008-05-28 |
2009-12-03 |
Glenmark Pharmaceuticals S.A. |
Dérivés d’imidazo[2,1-b]purine en tant que modulateurs de trpa1
|
DK2299821T3
(en)
|
2008-06-10 |
2016-02-15 |
Abbvie Inc |
Tricyclic compounds
|
GEP20146046B
(en)
|
2008-12-06 |
2014-02-25 |
Intracellular Therapies Inc |
Organic compounds
|
CA2740385A1
(fr)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Composes organiques
|
ES2638912T3
(es)
|
2008-12-06 |
2017-10-24 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
CN102238872A
(zh)
*
|
2008-12-06 |
2011-11-09 |
细胞内治疗公司 |
有机化合物
|
AU2009322905A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
SG171776A1
(en)
|
2008-12-06 |
2011-07-28 |
Intra Cellular Therapies Inc |
Organic compounds
|
EP2400970A4
(fr)
|
2009-02-25 |
2012-07-18 |
Intra Cellular Therapies Inc |
Inhibiteur de pde 1 pour troubles ophtalmiques
|
JP2012526810A
(ja)
|
2009-05-13 |
2012-11-01 |
イントラ−セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
SG181147A1
(en)
|
2009-12-01 |
2012-07-30 |
Abbott Lab |
Novel tricyclic compounds
|
CN108774237A
(zh)
|
2009-12-01 |
2018-11-09 |
Abbvie 公司 |
新的三环化合物
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
JP5894148B2
(ja)
|
2010-05-31 |
2016-03-23 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
JP5879336B2
(ja)
|
2010-05-31 |
2016-03-08 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
WO2011153138A1
(fr)
|
2010-05-31 |
2011-12-08 |
Intra-Cellular Therapies, Inc. |
Composés organiques
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
JP6549040B2
(ja)
|
2013-02-17 |
2019-07-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
AU2014234990B2
(en)
|
2013-03-15 |
2017-11-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US9545406B2
(en)
|
2013-03-15 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Method of treating a CNS injury with a PDE1 inhibitor
|
JP6696904B2
(ja)
|
2014-01-08 |
2020-05-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
製剤および医薬組成物
|
WO2015196186A1
(fr)
|
2014-06-20 |
2015-12-23 |
Intra-Cellular Therapies, Inc. |
Composés organiques
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ES2745819T3
(es)
|
2014-08-07 |
2020-03-03 |
Intra Cellular Therapies Inc |
Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
ES2857567T3
(es)
|
2014-09-17 |
2021-09-29 |
Intra Cellular Therapies Inc |
Derivados de 7,8-dihidro-[2h]-imidazo-[1,2-a]pirazolo[4,3-e]pirimidin-4(5h)-ona como inhibidores de fosfodiesterasa 1 (PDE1) para tratar enfermedades, trastornos o lesiones del sistema nervioso central (SNC)
|
RU2702732C1
(ru)
|
2014-12-06 |
2019-10-10 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
BR112017012007B1
(pt)
|
2014-12-06 |
2022-11-01 |
Intra-Cellular Therapies, Inc |
Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
CN116284011A
(zh)
|
2015-10-16 |
2023-06-23 |
艾伯维公司 |
制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
|
EP3436083A4
(fr)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
Nouvelles compositions et méthodes
|
ES2906107T3
(es)
|
2016-09-12 |
2022-04-13 |
Intra Cellular Therapies Inc |
Usos novedosos
|
EP3562828A1
(fr)
|
2016-12-28 |
2019-11-06 |
Dart NeuroScience LLC |
Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
|
US11434247B1
(en)
|
2017-11-27 |
2022-09-06 |
Dart Neuroscience Llc |
Substituted furanopyrimidine compounds as PDE1 inhibitors
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|